

Message Text

PAGE 01 STATE 116854
ORIGIN SNM-02

INFO OCT-01 ISO-00 MMO-04 AF-10 ARA-10 EA-09 EUR-12
NEA-10 IO-13 DEAE-00 CIAE-00 INR-07 JUSE-00
NSAE-00 TRSE-00 USIA-15 NSC-05 OES-07 OMB-01
HEW-06 /112 R

DRAFTED BY NIDA:PTHURBER/S/NM:MLCHESHES:AG
APPROVED BY S/NM:DHERNST
S/NM:DSOHLIN

-----211956Z 123656 /62

R 201823Z MAY 77
FM SECSTATE WASHDC
TO ALL DIPLOMATIC AND CONSULAR POSTS

UNCLAS STATE 116854

FOR NARCOTICS COORDINATORS, FROM FALCO-STATE, DUPONT, NIDA

E.O. 11652: N/A

TAGS: SNAR

SUBJECT: DRUG DEPENDENCE SECTION, WORLD PSYCHIATRIC
ASSOCIATION

1. WE ARE REQUESTING YOUR ASSISTANCE IN URGING YOUR HOST COUNTRY TO SEND A HEALTH PROFESSIONAL AS A REPRESENTATIVE TO THE DRUG DEPENDENCE SECTION ACTIVITIES PLANNED FOR THE VI WORLD CONGRESS OF PSYCHIATRY SPONSORED BY THE WORLD PSYCHIATRIC ASSOCIATION, TO BE HELD IN HONOLULU, HAWAII, AUGUST 28 - SEPTEMBER 4, 1977.
2. THE DRUG DEPENDENCE SECTION EVENTS AT THE CONFERENCE WILL INCLUDE DISCUSSIONS OF DRUG DEMAND REDUCTION FROM AN INTERNATIONAL PERSPECTIVE, PRESENTATIONS OF RECENT TECHNICAL INFORMATION BEARING ON DRUG DEPENDENCE TREATMENT, AND A UNCLASSIFIED
3. THE CONFERENCE PROMISES TO BE AN IMPORTANT OPPORTUNITY FOR DRUG DEPENDENCE POLICY AND TREATMENT EXPERTS TO ASSIMILATE A VARIETY OF VIEWS ON DEMAND REDUCTION, LEARN NEW DATA PERTINENT TO TREATMENT, ENGAGED IN PROBLEM-SOLVING IN THE AREA OF APPLYING EXISTING TECHNOLOGY, AND INTERACT

PAGE 02 STATE 116854

PROBLEM-SOLVING, POST-CONFERENCE SEMINAR WHICH WILL ADDRESS THE TECHNICAL AND POLICY ISSUES INVOLVED IN TRANSLATING DEMAND REDUCTION TECHNOLOGY TO MEET A GIVEN NATION'S PARTICULAR NEEDS AND CAPABILITIES.

WITH THEIR COUNTERPARTS FROM AROUND THE WORLD.

4. THE VALUE OF THIS CONFERENCE WOULD BE CONSIDERABLY ENHANCED IF ALL INTERNATIONAL NARCOTICS CONTROL DEMAND REDUCTION PRIORITY NATIONS WERE TO SEND REPRESENTATIVES. THEIR INVOLVEMENT IN THE FORMAL EVENTS AND PARTICIPATION IN INFORMAL DISCUSSIONS WOULD STIMULATE PLANS FOR FUTURE COLLABORATION TO THE BENEFIT OF ALL CONCERNED.

5. THE NATURE OF THE CONFERENCE IS SUCH THAT AN IDEAL REPRESENTATIVE WOULD BE A HEALTH PROFESSIONAL WHO IS INVOLVED IN BOTH THE FORMULATION OF DEMAND POLICY AND THE TECHNICAL ASPECTS OF POLICY IMPLEMENTATION. TO BRIEF YOU FURTHER ON CONFERENCE PARTICULARS, A SUMMARY OF THE DRUG DEPENDENCE SECTION ACTIVITIES IS ENCLOSED, AS IS THE PRELIMINARY CONFERENCE PROGRAM.

6. PLEASE INFORM MS. PAMELA THURBER, WORLD CONGRESS COORDINATOR, NATIONAL INSTITUTE ON DRUG ABUSE. 11400 ROCKVILLE PIKE, ROOM 844, ROCKVILLE, MARYLAND, USA 20852, OF POTENTIAL PARTICIPANTS IN ORDER THAT WE MIGHT PERSONALLY COMMUNICATE WITH THE INDIVIDUALS REPRESENTING YOUR COUNTRY.

7. FOR POSTS IN NCAP COUNTRIES: S/NM WILL BE WILLING TO FUND THE PARTICIPATION OF POLICY MAKERS OR PROGRAM DIRECTORS
UNCLASSIFIED

PAGE 03 STATE 116854

WHO MIGHT BENEFIT FROM THE CONGRESS, BUT WHO COULD NOT OTHERWISE ATTEND DUE TO BUDGETARY CONSTRAINTS. FYI: S/NM HAS ALREADY AGREED TO FUND THE PARTICIPATION OF DRS. NE WIN (BURMA), NOYA (BOLIVIA), VILLAREAL (MEXICO) AND CHIEN (HONG KONG). POSTS SHOULD CABLE NOMINATIONS AND JUSTIFICATIONS TO S/NM FOR CONSIDERATION.

8. THANK YOU FOR YOUR ATTENTION TO THIS MATTER.

DESCRIPTION OF DRUG DEPENDENCE SECTION ACTIVITIES:

A. DRUG DEPENDENCE SECTION ACTIVITIES

1. THE PLENARY SESSION: THE INTERNATIONAL CHALLENGE OF DRUG ABUSE.

THE OBJECTIVE OF THIS EVENT IS TO ESTABLISH DEMAND REDUCTION AS AN ISSUE OF INTERNATIONAL CONCERN WHICH REQUIRES THE INVOLVEMENT AND COLLABORATION OF POLICY MAKERS, LAW ENFORCEMENT, AND TREATMENT AND PREVENTION AT THE INTERNATIONAL REGIONAL, AND NATIONAL LEVELS.

AT THIS SESSION ON THE CONTEMPORARY PROBLEMS OF THE IMPORTANCE OF INTERNATIONAL DRUG ABUSE TREATMENT FOR DRUG

ABUSERS WILL BE DISCUSSED. THE EFFORTS OF INTERNATIONAL ORGANIZATIONS AND GOVERNMENTS OF EACH COUNTRY REPRESENTED WILL BE VIEWED. PARTICIPANTS WERE INVITED SO THAT THE MAJOR SEGMENTS OF THE WORLD WOULD BE REPRESENTED. EACH AREA OF THE WORLD TO INCLUDE SUCH ITEMS AS ESTIMATES OF THE NUMBER OF PATIENTS IN TREATMENT, THE NUMBER OF PERSONS WHO ARE USERS OF PRINCIPAL DRUGS OF ABUSE, THE NUMBER AND TYPES OF TREATMENT PROGRAMS IN OPERATION AS WELL AS THE CURRENT EFFORTS AND FUTURE PLANS OF THEIR COUNTRY IN THE FIELD OF DRUG ABUSE.

DISCUSSANTS:
UNCLASSIFIED

PAGE 04 STATE 116854

1) CHAIRMAN: ROBERT L. DUPONT, M.D., DIRECTOR,
NATIONAL INSTITUTE ON DRUG ABUSE, ROCKVILLE, MARYLAND.

2) DISCUSSANT: TOLANI ASUNI, M.D., PSYCHIATRIST,
NEUROPSYCHIATRIC HOSPITAL, ARO-ABECKULA, WESTERN STATE,
NIGERIA.

3) DISCUSSANT: GUIDO BELSASSO, M.D., DIRECTOR GENERAL,
DEL INSTITUTO NACIONAL DE ESTUDIO DEL TRABAJO,
PISA, MEXICO.

4) DISCUSSANT: DR. NE WIN, TADAGALE HOSPITAL,
PSYCHIATRIC HOSPITAL, RANGOON, BURMA.

5) DISCUSSANT: INAYAT KHAN, M.D., SENIOR MEDICAL OFFICER,
DRUG DEPENDENCE PROGRAM, OFFICE OF MENTAL HEALTH, WORLD
HEALTH ORGANIZATION, GENEVA, SWITZERLAND.

6) DISCUSSANT: GEORGE LING, PH.D., DIRECTOR, U.N.
DIVISION OF NARCOTIC DRUGS, GENEVA, SWITZERLAND.

7) DISCUSSANT: DR. M.R. MOHARRERI, ASSISTANT PROFESSOR
OF PSYCHIATRY, DEPARTMENT OF PSYCHIATRY, COLLEGE OF
MEDICINE, PAHLAVI UNIVERSITY SCHOOL OF MEDICINE, SHIRAZ,
IRAN.

8) DISCUSSANT: NILS T. NOYA, M.D., NATIONAL DIRECTOR OF
CONTROL OF DANGEROUS SUBSTANCES, DEPARTMENT OF MEDICINE -
SOCIOLOGY, LA PAZ, BOLIVIA.

2. SYMPOSIUM: THE BIOLOGICAL BASIS OF DRUG ABUSE -
THE SYMPOSIUM PRESENTS AND DISCUSSES THE IMPLICATIONS FOR
TREATMENT OF RECENT RESEARCH INTO THE BIOLOGICAL BASIS
OF DRUG ABUSE.

UNCLASSIFIED

PAGE 05 STATE 116854

AMONG THE TOPICS TO BE DISCUSSED ARE THE BIOLOGICAL MECHANISMS OF TOLERANCE AND PHYSICAL DEPENDENCE, THE BIOLOGICAL ASPECTS OF CANNABIS USE, BIOBEHAVIORAL STUDIES OF DRUG ABUSE LIABILITY, BIOBEHAVIORAL STUDIES OF NARCOTIC ANTAGONISTS, BIOSOCIAL ASPECTS OF OPIATE USE, CLINICAL PHARMACOLOGY OF NARCOTIC ABUSE, THE OPIATE RECEPTOR, BIOLOGICAL ASPECTS OF ALCOHOL DEPENDENCE AND ENDOCRINE CONCOMITANTS OF ALCOHOL ABUSE.

DISCUSSANTS:

1) CHAIRMAN: JACK H. MENDELSON, M.D., PROFESSOR OF PSYCHIATRY, HARVARD MEDICAL SCHOOL, AND DIRECTOR, ALCOHOL AND DRUG ABUSE RESEARCH CENTER, THE MCLEAN HOSPITAL, BELMONT, MASSACHUSETTS.

2) COSTAS STEFANIS, M.D., PROFESSOR OF PSYCHIATRY, UNIVERSITY OF ATHENS, ATHENS, GREECE.

3) DEMETRIUS JULIUS, M.D., DIRECTOR SOCIAL DEVELOPMENT CENTER, TEHRAN, IRAN.

4) TOMOJU YANAGITA, M.D., PROFESSOR OF PHARMACOLOGY, CENTRAL INSTITUTE FOR EXPERIMENTAL ANIMALS, KAWASAKI, JAPAN.

5) JULIAN E. VILLAREAL, M.D., PROFESSOR OF PHARMACOLOGY, INSTITUTO MILES DE TERAPEUTICA EXPERIMENTAL, MEXICO CITY, MEXICO.

6) JAMES M.N. CHIEN, SUPERINTENDENT OF SOCIAL SERVICES, SOCIETY FOR THE AID AND REHABILITATION OF DRUG ADDICTS, HONG KONG.

7) NANCY MELLO, PH.D., ASSOCIATE PROFESSOR, HARVARD MEDICAL SCHOOL, ASSOCIATE DIRECTOR OF THE ALCOHOL AND UNCLASSIFIED

PAGE 06 STATE 116854

DRUG ABUSE RESEARCH CENTER, MCLEAN HOSPITAL, BELMAR, MASSACHUSETTS.

3. SYMPOSIUM: NARCOTIC ANTAGONIST THERAPY: NALTREXONE -

THE EVOLUTION OF NARCOTIC ANTAGONIST THERAPY FOR THE TREATMENT OF OPIOID DEPENDENCE WILL BE TRACED FROM ITS THEORETICAL BASIS TO ITS CURRENT FEDERALLY SUPPORTED DRUG DEVELOPMENT PROGRAM. THERE WILL BE A DISCUSSION OF CONSIDERATIONS FOR AN OPTIMAL NARCOTIC ANTAGONISTS FOR THIS TYPE OF THERAPY. THE VARIOUS COMPOUNDS CONSIDERED FOR DEVELOPMENT WILL BE COVERED.

THE CURRENT NIDA-SUPPORTED NARCOTIC ANTAGONIST DEVELOPMENT PROGRAM, WHICH DEALS MAINLY WITH RESEARCH ON NALTREXONE (EN-1639A), WILL BE DESCRIBED IN ITS VARIOUS FACETS. THE NATIONAL ACADEMY OF SCIENCES' PLACEBO DOUBLE-BLIND STUDY OF NALTREXONE SAFETY AND EFFICACY WILL BE DISCUSSED. NALTREXONE USE IN A LARGE ADDICT POPULATION IN AN OPEN CLINICAL SETTING WILL BE DESCRIBED. THERE WILL ALSO BE DISCUSSION OF DEVELOPING NALTREXONE THERAPY WITHIN THE CONTEXT OF A BEHAVIORAL PARADIGM.

THE FINAL PHASE OF DEVELOPMENT, THAT OF WIDESPREAD CLINICAL TESTING, WILL BE DISCUSSED. IN ADDITION, PREPARATIONS, WILL BE DESCRIBED.

DISCUSSANTS:

1) CHAIRMAN: DEMETRIUS JULIUS, M.D., DIRECTOR, SOCIAL DEVELOPMENT CENTER, TEHRAN, IRAN.

2) PIERRE RENAULT, M.D., CHIEF, CLINICAL AND BEHAVIORAL BRANCH, DIVISION OF RESEARCH, NATIONAL INSTITUTE ON DRUG ABUSE, ROCKVILLE, MARYLAND.

UNCLASSIFIED

PAGE 07 STATE 116854

3) ROBERT WILLETTE, PH.D., CHIEF, RESEARCH TECHNOLOGY BRANCH, DIVISION OF RESEARCH, NATIONAL INSTITUTE ON DRUG ABUSE, ROCKVILLE, MARYLAND.

4) WILLIAM MARTIN, M.D., DIRECTOR, ADDICTION RESEARCH CENTER, DIVISION OF RESEARCH, LEXINGTON, KENTUCKY.

5) RICHARD B. RESNICK, M.D., DIRECTOR, DIVISION OF DRUG ABUSE RESEARCH AND TREATMENT, NEW YORK MEDICAL COLLEGE, NEW YORK.

6) CHARLES O'BRIEN, M.D., PH.D., ASSOCIATE PROFESSOR AND DIRECTOR, DRUG DEPENDENCE TREATMENT AND RESEARCH CENTER, V.A. HOSPITAL, PHILADELPHIA, PENNSYLVANIA.

SYMPOSIUM: LEVO-ALPHA-ACETYL METHADONE (LAAM): NEW DRUG FOR OLD HABITS.

THE SYMPOSIUM WILL INTRODUCE LAAM RESEARCH AND THE REASONS WHY LAAM HAS BEEN DEVELOPED; AND WILL REVIEW EARLY CLINICAL WORK. SUMMARIES WILL BE PRESENTED OF CURRENT CLINICAL APPLICATIONS. THE SYMPOSIUM WILL CONCLUDE WITH A DISCUSSION OF FUTURE APPLICATIONS OF LAAM AND ITS ROLE AS AN OPTION IN THE TREATMENT OF OPIOID ADDICTION.

DISCUSSANTS:

1) CHAIRMAN: WALTER LING, M.D. CHIEF, DRUG DEPENDENCE
TREATMENT PROGRAM, V.A. HOSPITAL, SEPULVEDA, CALIFORNIA.

2) JACK BLAINE, M.D., RESEARCH PSYCHIATRIST, CLINICAL
AND BEHAVIORAL BRANCH, DIVISION OF RESEARCH, NATIONAL
INSTITUTE ON DRUG ABUSE, ROCKVILLE, MARYLAND.

3) C. JAMES KLETT, PH.D., CHIEF, COOPERATIVE STUDIES
PROGRAM, AND CHIEF, CENTRAL NEUROPSYCHIATRIC LABORATORY,
UNCLASSIFIED

PAGE 08 STATE 116854

SUPPORT CENTER, V.A. HOSPITAL, PERRY POINT, MARYLAND.

4) JOHN A. SHYSNER, PH.D., PRESIDENT, JOHN WHYSNER
ASSOCIATES, WASHINGTON, D.C.

SYMPOSIUM: PSYCHOBIOLOGY OF DRUG ABUSE AND AFFECT
DISORDERS.

THE SYMPOSIUM WILL PRESENT RECENT RESEARCH IN THE AREAS
OF DRUG ABUSE AND EFFECT DISORDERS' AND PREVIOUSLY UN-
SUSPECTED MECHANISMS AND EFFECTS COMMON TO BOTH. THE
EMPHASIS WILL BE ON THE SYNTHESIS OF NEWLY-ACQUIRED
KNOWLEDGE INTO A COHERENT FRAMEWORK WHICH EMBRACES
ASPECTS OF ENDOGENOUS MENTAL ILLNESS AND DRUG ABUSE.

SPECIFIC TOPICS FOR DISCUSSION ARE THE IMPLICATIONS OF
POTENT, MORPHINE-LIKE ENDOGENOUS PEPTIDE FOR DRUG ABUSE
AND CLINICAL PSYCHIATRY, HYPOTHESES AND EVIDENCE LINKING
THIS "PLEASURE PEPTIDE" WITH ENDOGENOUS DISORDERS, STUDIES
OF THE EUPHORIC PROPERTY OF COCAINE; THE POSSIBLE ROLE
OF OPIATE ANTAGONISTS IN ALTERING MOOD AND COGNITION IN
NORMALS AND PSYCHOTIC PATIENTS, NEW FINDINGS ON THE
UNDERLYING PHYSIOLOGY OF ACUPUNCTURE-TREATED HEROIN WITH-
DRAWAL AND THE RELIEF OF ASSOCIATED DYSPHORIA BY ACUPUNC-
TURE, PARALLELS BETWEEN THE EFFECTS OF MANIC-DEPRESSIVE
ILLNESS ON MEMORY, AND RESEARCH FINDINGS ON MOOD-ALTERING
PSYCHOACTIVE COMPOUNDS.

DISCUSSANTS:

CHAIRMAN: RICHARD STILLMAN, M.D., RESEARCH PSYCHIATRIST,
NATIONAL INSTITUTE ON DRUG ABUSE, AND LABORATORY OF
CLINICAL PSYCHOPHARMACOLOGY, NATIONAL INSTITUTE OF MENTAL
HEALTH, BETHESDA, MARYLAND.

2) DENNIS MURPHY, M.D., CHIEF, SECTION ON CLINICAL
UNCLASSIFIED

PAGE 09 STATE 116854

NEUROPHARMACOLOGY, NATIONAL INSTITUTE ON MENTAL HEALTH,

BETHESDA, MARYLAND.

3) SOLOMON SNYDER, M.D., PROFESSOR OF PSYCHIATRY, JOHN HOPKINS MEDICAL SCHOOL, BALTIMORE, MARYLAND.

4) HERBERT WEINGARTNER, PH.D., NATIONAL INSTITUTE ON MENTAL HEALTH, BETHESDA, MARYLAND.

5) REESE JONES, M.D., PROFESSOR OF PSYCHIATRY, UNIVERSITY OF CALIFORNIA AT SAN FRANCISCO MEDICAL CENTER, SAN FRANCISCO, CALIFORNIA.

6) RICHARD JED WYATT, M.D., ACTING DIRECTOR, SPECIAL MENTAL HEALTH PROGRAMS, NATIONAL INSTITUTE OF MENTAL HEALTH, W.A. WHITE BUILDING, ST. ELIZABETH'S HOSPITAL, WASHINGTON, D.C.

7) DAVID STOFF, PH.D., RESEARCH PSYCHOLOGIST, LABORATORY OF CLINICAL PSYCHOPHARMACOLOGY, W.A. WHITE BUILDING, ST. ELIZABETH'S HOSPITAL, WASHINGTON, D.C.

POST-CONFERENCE SEMINAR: SIGNIFICANT ISSUES IN THE TRANSFER AND APPLICATION OF DRUG DEPENDENCE TECHNOLOGY.

THE ONE DAY SEMINAR IS DESIGNED TO STIMULATE THE FREE EXCHANGE OF VIEWPOINTS AND DATA AS THE MEMBERS ADDRESS THE COMPLEX DIFFICULTIES INVOLVED IN TRANSFERRING TREATMENT-RELATED TECHNOLOGY TO THE SITUATIONAL CONTEXTS OF THEIR PARTICULAR COUNTRIES. THE SEMINAR WILL BE STRUCTURED AROUND A SERIES OF QUESTIONS DEALING WITH VARIOUS FACETS OF DEMAND REDUCTION. THESE QUESTIONS ARE EXEMPLIFIED BY THE FOLLOWING:

-- WHAT ARE THE ISSUES WHICH MUST BE ADDRESSED IN ESTABLISHING A COHERENT DEMAND REDUCTION POLICY AND AN UNCLASSIFIED

PAGE 10 STATE 116854

EFFECTIVE SERVICE DELIVERY SYSTEM?

-- HOW CAN BOTH DEMAND REDUCTION AND SUPPLY REDUCTION EFFORTS BE COORDINATED TO FORM A BALANCED STRATEGY?

-- HOW DO DRUG ABUSE TREATMENT SERVICES RELATE TO THE MENTAL HEALTH OR EVEN BROADER PUBLIC HEALTH SERVICES DELIVERY SYSTEM?

-- WHAT ARE THE PROBLEMS INVOLVED IN CONDUCTING ADEQUATE ASSESSMENT TO PROVIDE BASIC DATA FOR DEMAND REDUCTION POLICY AND PROGRAMMING?

--WHAT ARE THE ISSUES WHICH MUST BE ADDRESSED IN DETERMINING AN APPROPRIATE ARRAY OF TREATMENT ALTERNATIVES?

-- WHAT ARE THE ADVANTAGES AND DISADVANTAGES OF INPATIENT VERSUS OUTPATIENT TREATMENT PROGRAMS?

-- WHAT IS THE ROLE OF METHADONE MAINTENANCE IN DRUG ABUSE TREATMENT?

-- WHAT ARE THE PRESENT AND PROJECTED MANPOWER NEEDS AND AVAILABILITY? WHAT OPTIONS EXIST FOR INCREASING MANPOWER CAPABILITY? WHAT CAN THE ROLE OF THE PARAPROFESSIONAL BE?

-- WHAT ARE THE ISSUES WHICH MUST BE ADDRESSED IN ORDER TO COLLABORATE IN REGIONAL EFFORTS OF TECHNICAL COOPERATION WITH OTHER COUNTRIES?

SEMINAR CHAIRMAN: ROBERT L. DUPONT, M.D., DIRECTOR, NATIONAL INSTITUTE ON DRUG ABUSE.

7. MONOGRAPH: DRUG DEPENDENCE PROCEEDINGS:

UNCLASSIFIED

PAGE 11 STATE 116854

THE MONOGRAPH WILL COMPILE THE PRESENTATIONS IN A SINGLE VOLUME FOR DISTRIBUTION TO DEMAND REDUCTION PROFESSIONALS.

EDITOR: ROBERT C. PETERSEN, PH.D., ASSISTANT DIRECTOR FOR PROGRAM INTEGRATION AND COORDINATION, DIVISION OF RESEARCH, NATIONAL INSTITUTE ON DRUG ABUSE, ROCKVILLE, MARYLAND.

8. DRUG DEPENDENCE SECTION RESOURCE CENTER:

THE RESOURCE CENTER WILL PROVIDE INFO WHICH WILL FACILITATE THE IDENTIFICATION OF U.S. RESOURCES, FROM NIDA AND ADAMHA, WHICH ARE AVAILABLE TO OTHER COUNTRIES IN THEIR DEMAND REDUCTION EFFORTS. THE RESOURCE CENTER WILL ALSO SERVE AS A CONNECTING POINT FOR PROFESSIONALS FROM OTHER COUNTRIES

WHO WISH TO FURTHER EXPLORE COLLABORATIVE EFFORTS IN DEMAND REDUCTION THROUGH EITHER REGIONAL EFFORTS AND/OR NIDA'S INTERNATIONAL TRAINING AND SUPPORT PROGRAMS. CHRISTOPHER

UNCLASSIFIED

<< END OF DOCUMENT >>

Message Attributes

Automatic Decaptioning: X
Capture Date: 22-Sep-1999 12:00:00 am
Channel Indicators: n/a
Current Classification: UNCLASSIFIED
Concepts: DRUGS, POLICIES, SCIENTIFIC MEETINGS
Control Number: n/a
Copy: SINGLE
Sent Date: 20-May-1977 12:00:00 am
Decaption Date: 01-Jan-1960 12:00:00 am
Decaption Note:
Disposition Action: n/a
Disposition Approved on Date:
Disposition Case Number: n/a
Disposition Comment:
Disposition Date: 01-Jan-1960 12:00:00 am
Disposition Event:
Disposition History: n/a
Disposition Reason:
Disposition Remarks:
Document Number: 1977STATE116854
Document Source: ADS
Document Unique ID: 00
Drafter: NIDA:PTHURBER/S/NM:MLCHESHES:AG
Enclosure: n/a
Executive Order: N/A
Errors: n/a
Expiration:
Film Number: D770182-0374
Format: TEL
From: STATE
Handling Restrictions: n/a
Image Path:
ISecure: 1
Legacy Key: link1977/newtext/t197705110/baaaevzz.tel
Line Count: 426
Litigation Code IDs:
Litigation Codes:
Litigation History:
Locator: TEXT ON-LINE, TEXT ON MICROFILM
Message ID: c36ce888-c288-dd11-92da-001cc4696bcc
Office: ORIGIN SNM
Original Classification: UNCLASSIFIED
Original Handling Restrictions: n/a
Original Previous Classification: n/a
Original Previous Handling Restrictions: n/a
Page Count: 8
Previous Channel Indicators:
Previous Classification: n/a
Previous Handling Restrictions: n/a
Reference: n/a
Retention: 0
Review Action: RELEASED, APPROVED
Review Content Flags:
Review Date: 16-Dec-2004 12:00:00 am
Review Event:
Review Exemptions: n/a
Review Media Identifier:
Review Release Date: n/a
Review Release Event: n/a
Review Transfer Date:
Review Withdrawn Fields: n/a
SAS ID: 2346305
Secure: OPEN
Status: NATIVE
Subject: DRUG DEPENDENCE SECTION, WORLD PSYCHIATRIC ASSOCIATION
TAGS: SNAR, US, XX
To: ALL DIPLOMATIC AND CONSULAR POSTS
Type: TE
vdkgvwkey: odbc://SAS/SAS.dbo.SAS_Docs/c36ce888-c288-dd11-92da-001cc4696bcc
Review Markings:
Margaret P. Grafeld
Declassified/Released
US Department of State
EO Systematic Review
22 May 2009
Markings: Margaret P. Grafeld Declassified/Released US Department of State EO Systematic Review 22 May 2009